EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice

Nilanjan Ghosh iD, Ashley Matusz-Fisher, Rupali Bose, Danielle Boselli iD, Gray Magee, Tommy Chen, Bei Hu iD, Tamara Moyo, Amy Soni, Steven Park, Edward Copelan, Belinda Avalos und 3 weitere

JCO Oncology Practice · 2025

DOI: 10.1200/op.24.00417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Nilanjan Ghosh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte,…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Tumor Lysis Syndrome, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Venetoclax has made a significant impact in the treatment of chronic lymphocytic leukemia (CLL) due to its ability to induce deep and durable remissions with a finite duration of oral therapy. However, it can lead to tumor lysis syndrome (TLS) which is mitigated with dose escalation strategies. Patients who initiate venetoclax need to follow rigorous, and potentially burdensome, TLS monitoring during dose ramp-up. The frequency with which this rigorous monitoring leads to therapeutic interventions in clinical practice has not been well described. We conducted a study to assess the incidence of TLS and interventions needed after initiation of venetoclax in patients with CLL. METHODS Adult patients with CLL who started treatment with venetoclax between July 2017 and March 2021 at Levine Cancer Institute were included in this study. Adherence to the venetoclax package insert (PI) for tumor lysis monitoring, incidence of laboratory as well as clinical TLS, and interventions resulting from the monitoring of TLS were collected. RESULTS We report outcomes on 73 consecutive patients with CLL who initiated venetoclax. The majority of patients had low (49%) or medium (44%) tumor burden. During venetoclax ramp-up, 66% of patients adhered strictly to TLS monitoring as per the venetoclax PI. One patient developed laboratory TLS, and no patients developed clinical TLS. Six patients received unplanned interventions to treat TLS; all had medium or high tumor burden. There were no unplanned interventions in patients with low tumor burden. CONCLUSION In patients with low and medium tumor burden CLL who start venetoclax, the incidence of TLS is very low, and interventions are uncommonly needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellTumor Lysis SyndromeBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic AgentsHumansMaleFemaleAgedMiddle AgedAged, 80 and overAdult

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC.
  • Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • Levine Cancer Institute, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC.

ORCID-Profile: Nilanjan Ghosh, Danielle Boselli, Bei Hu, James Symanowski, Derek Raghavan

Zitieren

APA

Ghosh, N., Matusz-Fisher, A., Bose, R., Boselli, D., Magee, G., Chen, T., Hu, B., Moyo, T., Soni, A., Park, S., Copelan, E., Avalos, B., Symanowski, J., Raghavan, D., & Jacobs, R. (2025). Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice. JCO Oncology Practice. https://doi.org/10.1200/op.24.00417

Vancouver

Ghosh N, Matusz-Fisher A, Bose R, Boselli D, Magee G, Chen T, et al. Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice. JCO Oncology Practice. 2025. doi:10.1200/op.24.00417

BibTeX
@article{Ghosh2025,
  author = {Ghosh, Nilanjan and Matusz-Fisher, Ashley and Bose, Rupali and Boselli, Danielle and Magee, Gray and Chen, Tommy and Hu, Bei and Moyo, Tamara and Soni, Amy and Park, Steven and Copelan, Edward and Avalos, Belinda and Symanowski, James and Raghavan, Derek and Jacobs, Ryan},
  title = {Evaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op.24.00417}
}
Kostenlos starten →